Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

AAV8-Specific Immune Adsorption Column: A Treatment Option for Patients with Pre-Existing Anti-AAV8 Neutralizing Antibodies

Anita Kruzik, PhD, Roland Raim, PhD, Dirk Voelkel, PhD, Markus Weiller, PhD, Werner Hoellriegl, PhD, Friedrich Scheiflinger, Hanspeter Rottensteiner, Birgit M Reipert, PhD, Maurus de la Rosa

Blood (2019) 134 (Supplement_1): 5922.

https://doi.org/10.1182/blood-2019-126730

Published: 2019

Journal Articles

The Factor VIII Variant X5 Enhances Hemophilia a Gene Therapy Efficiency By Its Improved Secretion

Franziska Horling, PhD, Johannes Lengler, PhD, Wenjing Cao, PhD, Biao Dong, PhD, Bagirath Gangadharan, Maurus De La Rosa, PhD, Werner Hoellriegl, PhD, Birgit M Reipert, PhD, Friedrich Scheiflinger, Weidong Xiao, PhD, Hanspeter Rottensteiner

Blood (2019) 134 (Supplement_1): 3356.

https://doi.org/10.1182/blood-2019-126489

Published: 2019

Journal Articles

Influence of Obesity on Factor IX Expression after Gene Therapy in a Mouse Model of Hemophilia B

Sogué Coulibaly, Markus Weiller, Alexander Bauer, Johannes Lengler, Stefan Romeder-Finger, Alexandra Kopić, Karima Benamara, Paul Monahan, Hanspeter Rottensteiner, Friedrich Scheiflinger, PhD, Marietta Turecek, Werner Hoellriegl, MD

Blood (2017) 130 (Supplement 1): 4878.

https://doi.org/10.1182/blood.V130.Suppl_1.4878.4878

Published: 2017

Journal Articles

Nonclinical Safety of SHP 826 (BAX 826), a Next Generation Extended Half-Life Recombinant Factor VIII Product

Veronika Ehrlich, Peter Leidenmuehler, Barbara Dietrich, Gerald Hoebarth, Tanja Ruthsatz, Peter L. Turecek, PhD, Martin Wolfsegger, Cstat (RSS), Alfred Weber, Herbert Gritsch, Werner Hoellriegl, Marietta Turecek

Blood (2016) 128 (22): 4977.

https://doi.org/10.1182/blood.V128.22.4977.4977

Published: 2016

Journal Articles

Nonclinical Assessment of Bax 604 (FEIBA STAR) - Reduced Volume Reconstitution & Higher Infusion Rate

Gerald Hoebarth, Alexandra Kopic, Martin Wolfsegger, Cstat (RSS), Alexander Bauer, Peter L. Turecek, PhD, Peter Leidenmuehler, Karima Benamara, Werner Hoellriegl, Marietta Turecek

Blood (2016) 128 (22): 2590.

https://doi.org/10.1182/blood.V128.22.2590.2590

Published: 2016

Journal Articles

Lethality of Mouse Tissue Factor Pathway Inhibitor Gene Disruption Is Rescued By Transgenic Human Tissue Factor Pathway Inhibitor Knock in

Robert Pachlinger, Rudolf Hartmann, Andrea Kolm, Erwin Panholzer, Nadja Ullrich, Fabian Knofl, Maria Schuster, Werner Hoellriegl, DVM, Friedrich Scheiflinger, PhD, Michael Dockal

Blood (2015) 126 (23): 3495.

https://doi.org/10.1182/blood.V126.23.3495.3495

Published: 2015

Journal Articles

Development of BAX 826, a Polysialylated Full-Length rFVIII with Significantly Improved PK Properties

Peter L. Turecek, PhD, Juergen Siekmann, PhD, Artur Mitterer, PhD, Michael Graninger, PhD, Gerald Schrenk, PhD, Peter Matthiessen, PhD, Hanspeter Rottensteiner, PhD, Werner Hoellriegl, DVM, Marietta Putz, MS, Hans Peter Schwarz, MD, Friedrich Scheiflinger, PhD

Blood (2015) 126 (23): 3536.

https://doi.org/10.1182/blood.V126.23.3536.3536

Published: 2015

Journal Articles

Pharmacokinetics of BAX 826, a Polysialylated Full-Length rFVIII, in Hemophilia a Mice, Rats, and Cynomolgus Monkeys

Alexandra Schiviz, DVM, Gerald Hoebarth, Martin Wolfsegger, Paolo Rossato, Alfred Weber, Herbert Gritsch, Hanspeter Rottensteiner, PhD, Peter L. Turecek, PhD, Friedrich Scheiflinger, PhD, Werner Hoellriegl, DVM, Marietta Putz, MS

Blood (2015) 126 (23): 1073.

https://doi.org/10.1182/blood.V126.23.1073.1073

Published: 2015

Journal Articles

A TFPI Inhibitory Half Life Extended Fusion Peptide Proves Efficacy in FVIII Knock out Mice and Marmoset Monkeys

Michael Dockal, PhD, Rudolf Hartmann, PhD, Thomas Polakowski, PhD, Erwin Panholzer, Willibald Kammlander, Frank Osterkamp, PhD, Ulrich Reineke, PhD, Alexandra Schiviz, PhD, Werner Hoellriegl, PhD, Friedrich Scheiflinger, PhD

Blood (2014) 124 (21): 1469.

https://doi.org/10.1182/blood.V124.21.1469.1469

Published: 2014

Journal Articles

Concomitant Administration Of Activated Prothrombin Complex Concentrate and Recombinant Activated Factor VII At Low Doses Are Efficacious and Safe In Hemophilic Mice

Michael Dockal, PhD, Sabine Knappe, PhD, Peter Leidenmuehler, Christina Piskernik, DVM, Sylvia Tippl, Marlene Resch, DVM, Dagmar Verdino, DVM, Alexander Bauer, Werner Hoellriegl, PhD, Friedrich Scheiflinger, PhD

Blood (2013) 122 (21): 2353.

https://doi.org/10.1182/blood.V122.21.2353.2353

Published: 2013

Journal Articles

Preclinical Efficacy Testing of Baxter's Recombinant ADAMTS13 in a Mouse Model of TTP.

Alexandra Schiviz, DVM, Marlene Resch, DVM, Elisa Farnleitner, Hanspeter Rottensteiner, PhD, Friedrich Scheiflinger, PhD, Hans Peter Schwarz, MD, Werner Hoellriegl, PhD, Eva-Maria Muchitsch, DVM

Blood (2012) 120 (21): 2216.

https://doi.org/10.1182/blood.V120.21.2216.2216

Published: 2012

Journal Articles

Impact of Factor IXa Content On Function, Safety and Efficacy of Recombinant Factor IX Products.

Wilfried Auer, PhD, Hanspeter Rottensteiner, PhD, Gerald Schrenk, PhD, Werner Hoellriegl, PhD, Alexandra Schiviz, DVM, Friedrich Scheiflinger, PhD, Hans Peter Schwarz, MD, Peter L Turecek, PhD, Eva-Maria Muchitsch, PhD

Blood (2012) 120 (21): 2233.

https://doi.org/10.1182/blood.V120.21.2233.2233

Published: 2012

Journal Articles

A new mouse model mimicking thrombotic thrombocytopenic purpura: correction of symptoms by recombinant human ADAMTS13

Alexandra Schiviz, Kuno Wuersch, Christina Piskernik, Barbara Dietrich, Werner Hoellriegl, Hanspeter Rottensteiner, Friedrich Scheiflinger, Hans Peter Schwarz, Eva-Maria Muchitsch

Blood (2012) 119 (25): 6128–6135.

https://doi.org/10.1182/blood-2011-09-380535

Published: 2012

Includes: Supplemental data

Journal Articles

Structural and Functional Characterization of Fucoidan and Its Procoagulant Effect in An Ex Vivo Model of Factor VIII-Inhibited Guinea Pigs

Michael Dockal, PhD, Werner Hoellriegl, Zhenqing Zhang, Susanne Till, PhD, Sabine Knappe, PhD, Michael Palige, PhD, Alexandra Schiviz, Hartmut J. Ehrlich, MD, Christina Szabo, Eva-Maria Muchitsch, Friedrich Scheiflinger, PhD

Blood (2011) 118 (21): 2262.

https://doi.org/10.1182/blood.V118.21.2262.2262

Published: 2011

Journal Articles

Peptides Inhibiting Tissue Factor Pathway Inhibitor Improve Hemostasis in Mice

Michael Dockal, PhD, Rudolf Hartmann, PhD, Thomas Polakowski, MBA, Osterkamp Frank, Hartmut J. Ehrlich, MD, Alexandra Schiviz, Werner Hoellriegl, Eva-Maria Muchitsch, Ulrich Reinecke, Friedrich Scheiflinger, PhD

Blood (2011) 118 (21): 24.

https://doi.org/10.1182/blood.V118.21.24.24

Published: 2011

Journal Articles

Pharmacokinetics of Baxter’s Longer Acting rFVIII (BAX 855) in Factor VIII Ko Mice, Rats and Cynomolgus Monkeys

Gerald Hoebarth, DVM, Susan Kubik, BSc, Martin Wolfsegger, PhD, John-Philip Lawo, Alfred Weber, PhD, Herbert Gritsch, Werner Hoellriegl, Alexandra Schiviz, Hartmut J. Ehrlich, MD, Friedrich Scheiflinger, PhD, Peter L Turecek, PhD, Hans Peter Schwarz, MD, Eva-Maria Muchitsch

Blood (2011) 118 (21): 4346.

https://doi.org/10.1182/blood.V118.21.4346.4346

Published: 2011

Journal Articles

Efficacy of Baxter’s Longer Acting rFVIII (BAX 855) in Mouse Models of Hemophilia A

Alexandra Schiviz, Eder Barbara, John-Philip Lawo, Hartmut J. Ehrlich, MD, Friedrich Scheiflinger, PhD, Peter L Turecek, PhD, Hans Peter Schwarz, MD, Eva-Maria Muchitsch, Werner Hoellriegl

Blood (2011) 118 (21): 4350.

https://doi.org/10.1182/blood.V118.21.4350.4350

Published: 2011

Journal Articles

Preclinical Efficacy Testing of Baxter's Recombinant FVIIa

Alexandra Schiviz, PhD, John-Philip Lawo, PhD, Marlene Resch, Peter Leidenmuehler, Bettina Bischetsrieder, Hartmut J. Ehrlich, MD, Friedrich Scheiflinger, PhD, Hans Peter Schwarz, MD, Werner Hoellriegl, PhD, Eva-Maria Muchitsch, PhD

Blood (2010) 116 (21): 4659.

https://doi.org/10.1182/blood.V116.21.4659.4659

Published: 2010

NARROW

AAV8-Specific Immune Adsorption Column: A Treatment Option for Patients with Pre-Existing Anti-AAV8 Neutralizing Antibodies

The Factor VIII Variant X5 Enhances Hemophilia a Gene Therapy Efficiency By Its Improved Secretion

Influence of Obesity on Factor IX Expression after Gene Therapy in a Mouse Model of Hemophilia B

Nonclinical Safety of SHP 826 (BAX 826), a Next Generation Extended Half-Life Recombinant Factor VIII Product

Nonclinical Assessment of Bax 604 (FEIBA STAR) - Reduced Volume Reconstitution & Higher Infusion Rate

Lethality of Mouse Tissue Factor Pathway Inhibitor Gene Disruption Is Rescued By Transgenic Human Tissue Factor Pathway Inhibitor Knock in

Development of BAX 826, a Polysialylated Full-Length rFVIII with Significantly Improved PK Properties

Pharmacokinetics of BAX 826, a Polysialylated Full-Length rFVIII, in Hemophilia a Mice, Rats, and Cynomolgus Monkeys

A TFPI Inhibitory Half Life Extended Fusion Peptide Proves Efficacy in FVIII Knock out Mice and Marmoset Monkeys

Concomitant Administration Of Activated Prothrombin Complex Concentrate and Recombinant Activated Factor VII At Low Doses Are Efficacious and Safe In Hemophilic Mice

Preclinical Efficacy Testing of Baxter's Recombinant ADAMTS13 in a Mouse Model of TTP.

Impact of Factor IXa Content On Function, Safety and Efficacy of Recombinant Factor IX Products.

A new mouse model mimicking thrombotic thrombocytopenic purpura: correction of symptoms by recombinant human ADAMTS13

Structural and Functional Characterization of Fucoidan and Its Procoagulant Effect in An Ex Vivo Model of Factor VIII-Inhibited Guinea Pigs

Peptides Inhibiting Tissue Factor Pathway Inhibitor Improve Hemostasis in Mice

Pharmacokinetics of Baxter’s Longer Acting rFVIII (BAX 855) in Factor VIII Ko Mice, Rats and Cynomolgus Monkeys

Efficacy of Baxter’s Longer Acting rFVIII (BAX 855) in Mouse Models of Hemophilia A

Preclinical Efficacy Testing of Baxter's Recombinant FVIIa

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only